A panel of medical experts begin a discussion addressing the incidence and prevalence of chronic kidney disease (CKD).
Chronic Kidney Disease Stakeholder Summit
Dr Haumschild drives a conversation regarding CKD treatment in the presence comorbidities such as cardiovascular disease and type 2 diabetes.
The screening process for CKD is discussed by Susanne Nicholas, MD, MPH, PhD.
Clinical and financial considerations surrounding screening and early intervention for CKD are discussed by key opinion leaders.
Dr Nicholas highlights key objectives in developing CKD treatment strategies.
The current treatment landscape for CKD patients with preexisting comorbidities is explored.
Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD.
Medical experts discuss considerations for ESRD during CKD treatment as well as updated guidelines for treatment of chronic kidney disease.
Ken Cohen, MD, illustrates payer programs designed to support patient care in CKD treatment.
John Anderson, MD, discusses the management of quality care for patients with CKD.
Barriers inhibiting optimal CKD treatment for patients are underlined.
Medical experts highlight the financial benefit of early CKD intervention.
Expert panelists share final points of emphasis regarding treatment for CKD.
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
4
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
5
